When is ruxolitinib cream (Opzelura) expected to be launched in China?

Ruxolitinib cream (Opzelura) is an innovative targeted drug used to treat specific skin diseases and has received widespread attention in the international market in recent years. At present, this drug has not been officially launched in China, so domestic patients are temporarily unable to purchase ruxolitinib cream through regular channels.

Regarding the launch time of ruxolitinib cream in China, there is currently no clear official approval or launch announcement. The drug introduction and approval process usually requires multiple steps such as clinical trial data review, drug registration application, and drug regulatory department evaluation. This process is often time-consuming. It is expected that with the advancement of relevant applications and policy support, domestic marketing authorization may be gradually obtained in the next few years.

Since the domestic market has not yet opened, some patients may choose to purchase ruxolitinib cream through overseas channels. The price of foreign original drugs is relatively high, usually as high as more than 10,000 yuan per box, which puts greater financial pressure on patients. At the same time, there are also generic versions of drugs from Bangladesh and other countries on the overseas market. The price is only a few tenths of the original drug, about a few hundred yuan, and the drug ingredients are basically the same as the original drug, providing a more affordable option for patients with limited economic conditions.

In general, although ruxolitinib cream has not yet been launched in China, it is expected to enter the Chinese market in the future with the advancement of drug approval and the growth of patient demand. While waiting, patients should obtain drug information through formal channels and choose appropriate treatment plans under the guidance of doctors to ensure drug safety and therapeutic effects.

Reference materials:https://www.opzelura.com/